Work

MAGE-A3 expression in patients screened for the DERMA trial: A phase III trial testing MAGE-A3 immunotherapeutic in the adjuvant setting for stage IIIB-C-Tx melanoma.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.8559

Authors: John F Thompson, Mario Santinami, Thomas Jouary, Eugeny Levchenko, Bernard Mark Smithers, Laurent Mortier, Jean Jacques Grob, Uwe Trefzer, Ralf Gutzmer, Corinne Jamoul, Olivier Peeters, Brigitte Dreno, John M. Kirkwood

Institutions: Melanoma Institute Australia, Fondazione IRCCS Istituto Nazionale dei Tumori, Hôpital Saint-André, Institute of Oncology NN Petrov, Princess Alexandra Hospital, Centre Hospitalier Universitaire de Lille, Assistance Publique Hôpitaux de Marseille, Charité – Universitätsmedizin Berlin, Medizinische Hochschule Hannover, GlaxoSmithKline (Belgium), Centre Hospitalier Universitaire de Nantes, UPMC Hillman Cancer Center

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602327226

Cites:

Cited by: 2

Related to: 10